Discovery of a novel and potent KRAS<sup>G12V</sup>-targeting peptide with antiproliferative activity against colorectal cancer cells.
Peptide-1 shows promise as a KRAS<sup>G12V</sup>-targeting peptide in colorectal cancer, but further research is needed to validate its efficacy in clinical settings.
Where it sits
this study against the rest of the p21 (p021) corpusSummary and findings
This study identified Peptide-1 as a KRAS<sup>G12V</sup>-targeting peptide through virtual screening of a peptide library. Peptide-1 exhibited potent antiproliferative activity against colorectal cancer cells while showing weaker effects on normal cells. The study suggests further investigation into Peptide-1 for colorectal cancer drug discovery.
Abstract
Despite the clinical relevance of KRAS<sup>G12V</sup> in colorectal cancer, KRAS<sup>G12V</sup>-specific inhibitors remain limited. Through structure-based virtual screening of a 59,319-member peptide library, we identified four KRAS<sup>G12V</sup>-targeting peptides, among which Peptide-1 showed the most favourable docking profile. MST assays confirmed Peptide-1 had the highest affinity among Peptides 1-4, with stronger binding to KRAS<sup>G12V</sup> than to other KRAS mutants. Structural analysis, molecular dynamics simulations, and free-energy calculations indicated that Peptide-1 formed a stable and energetically favourable complex with KRAS<sup>G12V</sup> through extensive hydrogen bonding and hydrophobic interactions. Peptide-1 showed favourable human serum stability and cellular NanoBRET-supported engagement with KRAS<sup>G12V</sup>. Functionally, Peptide-1 displayed potent antiproliferative activity in colorectal cancer cell lines, weaker effects on normal cells and reduced efficacy after KRAS<sup>G12V</sup> knockdown. In SW480 cells, Peptide-1 was associated with reduced ERK1/2 phosphorylation, p21 upregulation, and G0/G1 accumulation. Overall, these findings support further investigation of Peptide-1 as a KRAS<sup>G12V</sup>-targeting peptide for colorectal cancer drug discovery.
Background
The study addresses the challenge of targeting KRAS<sup>G12V</sup> in colorectal cancer, a mutation associated with poor prognosis and limited treatment options. Prior research has highlighted the scarcity of specific inhibitors for this mutation. This study is significant as it explores a novel peptide approach to potentially inhibit KRAS<sup>G12V</sup> activity.
Methods
The study utilized structure-based virtual screening of a 59,319-member peptide library to identify KRAS<sup>G12V</sup>-targeting peptides. The primary outcome measure was the binding affinity of Peptide-1 compared to other peptides, assessed through MST assays. The effects of Peptide-1 on colorectal cancer cell lines were evaluated, including cellular engagement and functional assays.
Results
Peptide-1 exhibited the highest affinity for KRAS<sup>G12V</sup> among the tested peptides. The study reported that Peptide-1 displayed potent antiproliferative activity in colorectal cancer cell lines and was associated with reduced ERK1/2 phosphorylation and increased p21 levels in SW480 cells.
Interpretation
These findings suggest that Peptide-1 may be a promising candidate for targeting KRAS<sup>G12V</sup> in colorectal cancer. However, the clinical significance of the observed effects remains uncertain due to the lack of in vivo data and the reliance on in vitro models. The study's limitations, including potential confounding factors and the absence of human data, warrant caution in interpreting the results.
Key findings
- Peptide-1 showed the highest affinity among Peptides 1-4 in MST assays.
- Peptide-1 had stronger binding to KRAS<sup>G12V</sup> than to other KRAS mutants.
- Peptide-1 displayed potent antiproliferative activity in colorectal cancer cell lines.
- Reduced efficacy of Peptide-1 was observed after KRAS<sup>G12V</sup> knockdown.
- In SW480 cells, Peptide-1 was associated with reduced ERK1/2 phosphorylation and p21 upregulation.
Limitations
- In vitro findings only, no in vivo validation.
- Small sample size for specific assays not reported.
- Potential confounding factors not fully addressed.
- Lack of long-term follow-up on effects.